Articles with "shareholder celgene" as a keyword



SAT0225 Cereblon modulator CC-220 decreases naÏve and memory B cells and plasmacytoid dendritic cells in systemic lupus erythematosus (SLE) patients: exposure-response results from a phase 2A proof of concept study

Sign Up to like & get
recommendations!
Published in 2017 at "Annals of the Rheumatic Diseases"

DOI: 10.1136/annrheumdis-2017-eular.3036

Abstract: Background CC-220 is a cereblon E3 ligase modulatory compound currently in development for the treatment of Systemic Lupus Erythematosus as well as other autoimmune conditions and multiple myeloma. As a high affinity ligand for cereblon,… read more here.

Keywords: sle; employee celgene; celgene employee; celgene ... See more keywords